Emergent Biosolutions EBS Contracts and grants — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's contracts and grants — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's contracts and grants — total revenues?
- Emergent Biosolutions (EBS) reported contracts and grants — total revenues of $6.4M in Q1 2026.
- How has Emergent Biosolutions's contracts and grants — total revenues changed year-over-year?
- Emergent Biosolutions's contracts and grants — total revenues decreased by 51.1% year-over-year, from $13.1M to $6.4M.
- What is the long-term trend for Emergent Biosolutions's contracts and grants — total revenues?
- Over 4 years (2021 to 2025), Emergent Biosolutions's contracts and grants — total revenues has grown at a -25.7% compound annual growth rate (CAGR), from $123.8M to $37.7M.
- What does contracts and grants — total revenues mean?
- This metric represents the total revenue recognized from government-funded research, development, and procurement contracts or grants within a specific business segment. It captures the financial contribution of non-commercial partnerships aimed at public health initiatives and product development. Investors use this to assess the company's success in securing public sector funding and the stability of its long-term government-backed revenue streams.